Sunday, September 22, 2019

PEB Is Seeking Collaboration In:

 


 

 

PEB-108

Utilizing its patented DPS-BsAb technology, Princeton Enduring Biotech (PEB or PE Biotech) has developed its first, proof of concept drug candidate PEB-108.  Study showed that PEB-108 was capable of redirecting immune effector T cell to kill cancer cells. We are seeking collaboration to move PEB-108 into IND.